Want to join the conversation?
For 2Q16, $MYL posted adjusted GM of 56%, up approx. 200 BP vs. 2Q15 and 1Q16 due to new product introductions and favorable Specialty sales. Adjusted R&D expense rose slightly vs. 2Q15 as the company continues to invest in its respiratory, insulin and biologics programs. SG&A remained unchanged at approx. 21% of total revenues.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.